Skip to main content

Nightstar Therapeutics plc Sponsored ADR News

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.

Dow Tumbles as Rally Spurred by Trade Deal Hopes Fades

Stocks recoup some losses in late trading but close lower as momentum from a report that China and the U.S. are in the final stages of completing a trade deal fades.

Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

Biogen will purchase Nightstar Therapeutics in an all-cash deal that values the British gene-therapy company at $877 million.

Amgen: Analysts' Upgrades, Downgrades

Amgen is upgraded from hold to buy by Citigroup.

Technical Setups: News Corp., RBS

These stocks, including News Corp. and Royal Bank of Scotland, could be staging a technical move.

Breaking News

A New Take on the Big Mac (May Be) Headed to U.S. McDonald's Menus

This is very different than the Big Mac you know and love.

Crypto Evangelist Mark Cuban Is in Trouble

The billionaire and crypto investor was in business with Voyager Digital which went bankrupt early July.

We're Enduring 'Housing Recession,' Homebuilders' Economist Says

The builder confidence index breached the break-even measure of 50 in August for the first time since May 2020.

Elon Musk Pampers His Ties with China

China is a crucial country for Tesla for its domination of the market of electric vehicles.